NCT00798096View on ClinicalTrials.gov

Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
T Cell Lymphoma
Interventions
DRUG

Fostamatinib Disodium

200 mg PO BID

Trial Locations (10)

10021

Research Site, New York

30322

Research Site, Atlanta

55905

Research Site, Rochester

68198

Research Site, Omaha

77030

Research Site, Houston

94143

Research Site, San Francisco

94305

Research Site, Stanford

02115

Research Site, Boston

V5Z 4E6

Research Site, Vancouver

M5G 2M9

Research Site, Toronto

Sponsors
All Listed Sponsors
lead

Rigel Pharmaceuticals

INDUSTRY